[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"icd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:icd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,78,107,134,157,186,224,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100400829","improving-patient-reported-outcome-measures-in-catheter-ablation-100400829",false,"NCT04499326","Improving Patient Reported Outcome Measures in Catheter Ablation","Use of Patient Reported Outcome Measures (PROMs) to Assess Quality of Life and Economic Evaluation of Cardiac Catheter Ablation of Ventricular Tachycardia: a Feasibility and Cohort Study","Inclusion Criteria:\n\nAdults (\\>18 years) With an Implantable Cardioverter Defibrillator (ICD) implanted \\>3 months from time of recruitment and a previous episode of documented VT requiring therapy from the ICD.\n\nAnd impaired LV\u002FRV function Willing and able to give written informed consent\n\nExclusion Criteria:\n\nPatients who are planning to move away from study site within 12 months of enrolment who wished to use postal method to complete their HRQL Patients who are unable to give informed consent","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will assess whether more frequent measurement of patient reported outcome measures (PROMs) - specifically health related quality of life (HRQL) - can improve the evaluation of the clinical effectiveness and cost-effectiveness of catheter ablation of ventricular tachycardia (VT) in patients with an Implantable Cardioverter Defibrillator (ICD).\n\nIt is designed to have feasibility outcomes which contribute to answering the above.",[26,27,28],"Ventricular Tachycardia","ICD","Quality of Life",[30,31,32],"Catheter ablation","Patient reported outcome measure","Incremental cost effectiveness ratio","RECRUITING","2026-02-26",{"date":36,"type":37},"2026-03-02","ACTUAL",{"date":39,"type":37},"2024-06-13",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Barts & The London NHS Trust","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100621559","left-bundle-branch-pacing-in-patients-with-hypertrophic-cardiomyopathy-after-myectomy-100621559","NCT07372196","Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy","LEFTpaceHCM","Inclusion criteria:\n\n* Men and women aged 18 years and older;\n* Patients with post-myectomy HCM who develop LBBB with a QRS complex greater than 130 ms and a high risk of SCD (HCM Risk-SCD ≥ 6%);\n* Signed informed consent to participate in the study;\n\nExclusion criteria:\n\n* Absence of QRS complex morphology consistent with LBBB in LBBB with a positive QRS complex less than 130 ms;\n* Presence of baseline complete RBBB;\n* Heart transplantation or implantation of an LVAD is planned within the next 6 months;\n* Patients with intermediate or low risk of SCD;\n* History of AMI less than three months prior to study inclusion;\n* Acute renal and hepatic failure;\n* Acute infectious diseases;\n* Presence of mental illness;\n* Presence of other illnesses for which life expectancy is less than one year;\n* Patient refusal to participate in the study at any stage;","75 Years",{"count":55,"type":20},30,[23],"Pilot interventional randomized clinical trial to study the efficacy of left bundle branch pacing in patients with hypertrophic cardiomyopathy after myectomy for the prevention of progression of heart failure, prevent the occurrence of life-threatening rhythm disturbances and promote reverse remodeling of the LV.\n\nThe aim of the study is to evaluate the comparative efficacy and safety of implantation of a cardioverter-defibrillator with left bundle branch block pacing and a dual-chamber cardioverter-defibrillator in patients with HCM and complete left bundle branch block after myectomy at high risk of SCD.\n\nObjectives of the study:\n\n1. To analyze the safety of ICD implantation procedures with LBBB pacing in patients with HCM and LBBB after myectomy at high risk of SCD;\n2. To develop a technique for LBBB lead implantation in patients with HCM and LBBB after myectomy;\n3. To conduct a comparative analysis of QRS complex duration data based on ECG data before and after surgery, LV activation time, and pacing threshold based on postoperative programming data;\n4. To conduct a comparative analysis of the functional class of CHF, NT-proBNP, the presence\u002Fabsence of interventricular and intraventricular dyssynchrony, the degree of diastolic dysfunction, LVEF, and LV EDV based on echocardiography data before and 12 months after surgery;\n5. Conduct a comparative analysis of QRS complex duration data based on ECG data, LV activation time, pacing threshold, the presence of recorded episodes of AF, VT, VF, antitachycardia and shock therapy according to programming data at 3, 6, and 12 months after surgery;\n6. Assess quality of life before and 12 months after surgery using the KCCQ-12 questionnaire; 30 patients (15 patients in each group) will be randomly separated into 2 groups. All participants go through ICD programming at 3, 6, and 12 months after myectomy, assessment of left ventricular remodeling based on ECG and echocardiography, NT-proBNP, assessment of quality of life before surgery and 12 months after surgery.",[59,60,61,27,62],"HCM - Hypertrophic Cardiomyopathy","Sudden Cardiac Death","Left Bundle Branch Pacing","Heart Failure (HF)",[64,65,61,27,66,67],"sudden cardiac death","Hypertrophic Cardiomyopathy","Heart failure","myectomy","2026-01-20",{"date":70,"type":37},"2026-01-28",{"date":72,"type":37},"2025-11-14",{"date":74,"type":20},"2027-07-01",{"name":76,"class":77},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100619239","prospective-study-of-lead-associated-tricuspid-regurgitation-in-patients-undergoing-new-transvalvular-lead-insertion-100619239","NCT07342036","Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion","LITR","Inclusion Criteria:\n\n* medically indicated for pacemaker, ICD- or CRT implantation\n* No previous diagnosis of severe tricuspid regurgitation on enrollment\n* No existing transvalvular device (must be first implantation)\n* No other diagnosed severe valvular heart disease\n* Not previous diagnosis with pre-capillary pulmonary hypertension\n* No previous diagnosis of structural disease of the right ventricle (i.e. ACM, cardiac sarcoidosis, carcinoid...)\n\nExclusion Criteria:\n\n* Patients unable to give consent\n* Under the age of 18 years\n* Relevant pre-capillary pulmonary hypertension according to decision of the heart-team (sPAP echo \\>70 mmHg)\n* Severe tricuspid valve regurgitation (Grade 3 or worse) on enrollment\n* Patients who have undergone Lead-explantation\n* Exisiting valvular heart disease requiring treatment according to the decision of the heart-team. These patients may be enrolled in the study following treatment.\n* Previous tricuspid valve surgery\n* Patients with congenital heart disease (i.e. tetralogy of fallot, Ebstein's anomaly,...)\n* Pregnant or breastfeeding women\n* Life expectancy \\\u003C 12 months",{"count":86,"type":20},200,"1 Year","OBSERVATIONAL","The goal of this clinical trial is to record the incidence of newly developed or worsening tricuspid valve regurgitation (TR) following the implantation of a pacemaker or defibrillator with a transvenous lead. To collect this data, a transthoracic echocardiogram (TTE) with 3D imaging of the tricuspid valve (TV) will be performed before and after pacemaker implantation, with particular emphasis on assessing the tricuspid valve. Additionally, routine follow-up visits will be conducted at 6 and 12 months post-intervention, during which a TTE, ECG, NT-proBNP measurement, and pacemaker check will be performed.",[91,92,27,93],"Tricuspid Valve Regurgitation","Pacemaker","Left Bundle Branch Area Pacing",[95,96,97],"tricuspid regurgitation","lead-related TR","lead-associated TR","2026-01-14",{"date":100,"type":37},"2026-01-16",{"date":102,"type":37},"2024-07-19",{"date":104,"type":20},"2027-01-30",{"name":106,"class":44},"Hazem Omran",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100601034","virtual-reality-in-electrophysiological-procedures-and-device-implantation-the-vr-inep-trial-100601034","NCT07105241","Virtual Reality in Electrophysiological Procedures and Device Implantation: the VR inEP Trial","VR inEP","Inclusion Criteria:\n\n* ≥16 years of age\n* Planned to undergo an invasive electrophysiological procedure (e.g., catheter ablation or electrophysiological study) or cardiac device implantation (e.g., pacemaker or implantable cardioverter defibrillator).\n* The procedure must be performed under local anesthesia.\n\nExclusion Criteria:\n\n* Patients undergoing procedures using (conscious) sedation\n* Patients who do not speak or understand Dutch\n* History of dementia\n* Severe visual impairment.","16 Years",{"count":116,"type":20},115,[23],"Each year about 37,000 patients undergo a catheter ablation to treat cardiac arrhythmias or have a cardiac device such as a pacemaker or implantable cardioverter defibrillator implanted in the Netherlands. Although the procedures positively impact health related outcomes on the long term, they are often accompanied by periprocedural pain and anxiety on a shorter term. These negative effects can be prevented or treated by pharmacological interventions (e.g. analgesics or benzodiazepines), but side effects of these drugs may compromise patient safety and extend hospital admissions. Distraction using Virtual Reality (VR) may be an attractive non-pharmacological alternative.\n\nIt is the aim of the Virtual Reality in Electrophysiological Procedures and device implantation (VR inEP) trial to study the feasibility and efficacy of VR to decrease experienced pain and anxiety in patients undergoing invasive procedures for arrhythmias and conduction disorders. The study also serves as a stepping stone towards structural implementation of VR into clinical care, by familiarizing care personnel of the cardiac catheterization rooms with the use of VR, its indications and logistics, and identifying potential barriers for structural implementation of VR.\n\nVR inEP is a single-center, open label, randomized controlled trial performed in the catheterization rooms in the Radboudumc. Adult patients undergoing an electrophysiological procedure (e.g., catheter ablation or electrophysiological study) or cardiac device implantation (e.g., pacemaker or implantable cardioverter defibrillator) performed under local anesthesia are eligible for inclusion. Patients consenting to participate are randomized in a 1:1 ratio to the VR intervention or control group, stratified for the indication for the procedure (50% electrophysiological procedures, 50% cardiac device implantations). Patients and their treatment teams are unblinded for the treatment allocation. The primary outcomes are pain perception and anxiety during the procedure as a whole, quantified using the visual analog scale (VAS) for pain and the numeric ranking scale (NRS) for anxiety, 30 minutes after the procedure ends.",[120,121,122,123,92,27],"Arrhythmia","Cardiac Implantable Electronic Device","Ablation of Arrhythmias","Electrophysiologic Study","NOT_YET_RECRUITING","2025-07-29",{"date":127,"type":37},"2025-08-05",{"date":129,"type":20},"2025-11-15",{"date":131,"type":20},"2026-07-31",{"name":133,"class":44},"Radboud University Medical Center",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":45},"100313243","prospective-database-for-prediction-of-atrial-fibrillation-in-pacemaker-and-icd-patients-100313243","NCT03357926","Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients","SAFE-ME - Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients","SAFE-ME","Inclusion Criteria:\n\n* Implanted pacemaker or implanted cardioverter defibrillator (ICD) with atrial lead\n* CHADS-VASc Score of 2 or more\n* Sinus rhythm or atrial paced rhythm\n* Atrial stimulation rate 50% or less\n* ModeSwitch rate 50% or less since last pacemaker interrogation\n\nExclusion Criteria:\n\n* pacemaker or ICD malfunction\n* atrial fibrillation (AF) at time of pacemaker \u002F ICD interrogation\n* AF during 24-hour Holter ECG monitoring\n* permanent AF",{"count":143,"type":20},250,"Atrial fibrillation (AF) is associated with a five-fold increased risk of cerebrovascular stroke. While the risk of stroke in patients with known AF can be calculated via AF stroke prediction risk scores, the prediction of AF occurrence per se in individual patients remains difficult.\n\nWe will recruit 250 patients with an implanted dual-chamber Pacemaker (PM) or an implantable cardioverter Defibrillator (ICD) with atrial lead to ensure continuous rhythm monitoring during follow up. At baseline, we will gather clinical and device data of patients. For AF prediction based on surface Electrocardiography (ECG), 24-h Holter ECG monitoring will be performed. After 6 months, we will assess the occurrence of AF during the study period via interrogation of PM\u002FICD. The resulting data will be used to develop algorithms including clinical, device and ECG data for prediction of the development of AF in individual patients. If possible, we will develop a risk score of high accuracy by combination of demographical, clinical and technical parameters of device patients. The resulting risk score could potentially help to facilitate the decision if anticoagulation is necessary in patients with either risk of AF or embolic stroke of unknown origin. Furthermore, Hayn et al. (AIT Austrian Institute of Technology) are currently developing algorithms to predict the occurrence of AF surface ECG data. It is an additional aim of this project to support the development of this algorithm in pacemaker and ICD patients and to increase the accuracy of AF prediction with clinical parameters and other parameters available to patients with implanted pacemaker (PM) or implanted cardioverter-defibrillator (ICD).",[146,147,27],"Atrial Fibrillation","Pacemaker Ddd","2024-11-19",{"date":150,"type":37},"2024-11-21",{"date":152,"type":37},"2017-03-01",{"date":154,"type":20},"2025-12",{"name":156,"class":44},"Medical University of Graz",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":166,"conditions":167,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":45},"100394507","pacing-to-maintain-physiologic-ventricular-activation-100394507","NCT04416958","Pacing to Maintain Physiologic Ventricular Activation","Pacing for Cardiac Resynchronisation Using the Intrinsic Conduction System to Maintain Physiologic Ventricular Activation","Pace-Conduct","Inclusion Criteria:\n\n* Pacemaker or ICD Implantation aiming to avoid pacing induced ventricular dyssynchrony according to current guidelines\n* age \\>= 18 years\n\nExclusion Criteria:\n\n* no informed consent for the procedure given\n* no follow-up data",{"count":86,"type":20},"Right ventricular pacing causes ventricular dyssynchrony and may be associated with impaired outcome. In the last decade, several approaches for more physiological pacing became available and were implemented in the latest guidelines. However, compared to conventional device implantation, cardiac resynchronization, His bundle pacing and left bundle area pacing remain demanding procedures in the individual case. Goal of the single center observational \"Pace conduct\" study is to evaluate implantation success, safety and outcome of pacing methods that maintain physiologic ventricular activation.",[168,169,170,171,172,27],"Pacemaker DDD","His Bundle Pacing","LBB Area Pacing","Pacing-Induced Cardiomyopathy","Left Bundle-Branch Block",[174,175,176],"His bundle pacing","LBB area pacing","cardiac resynchronisation therapy","2024-10-11",{"date":179,"type":37},"2024-10-15",{"date":181,"type":37},"2018-01-01",{"date":183,"type":20},"2030-12-31",{"name":185,"class":44},"Klinikum-Fuerth",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":205,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100556058","evaluation-of-the-effectiveness-of-two-methods-of-regional-anesthesia-during-s-icd-implantation-procedure-100556058","NCT06520150","Evaluation of the Effectiveness of Two Methods of Regional Anesthesia During S-ICD Implantation Procedure.","Evaluation of the Effectiveness of Two Methods of Regional Anesthesia During Subcutaneous Implantable Cardioverter-defibrillator (SICD) Implantation Procedure.","Inclusion Criteria:\n\n* patients aged 18-90 years requiring S-ICD implantation for cardiac indications,\n* high risk of anesthesia (ASA II or higher), patients giving informed consent to participate in the study.\n\nExclusion Criteria:\n\n* absolute contraindications to regional anesthesia such as generalized coagulation disorders, inflammation at the site of anesthesia, allergy to the drugs used for regional anesthesia\n* lack of consent of the patient for the conducted procedure,\n* inability to cooperate with the patient - such as severe mental retardation, unregulated mental illness with motor agitation, advanced neurodegenerative diseases such as Parkinson's disease\u002FAlzheimer's,\n* inability to give informed consent to participate in the study.","90 Years",{"count":195,"type":20},32,[23],"Our study consists of a combination of regional blockade ('local' anesthesia) of the anterior and lateral chest wall in the form of a thin needle prick and the supply of local anesthetic drugs to the area of the relevant chest wall structures to exclude all stimuli, including pain from the operative site. A short-acting analgesic and sedative drug will be administered intravenously throughout the procedure - in a dose that allows the required contact between the patient and the anesthetist. If necessary, the dose of the drug may be increased to maintain pain comfort throughout the procedure.\n\nThe anesthetic team will be with the patient throughout the procedure to ensure comfort and safety.",[199,200,201,202,203,204,27],"Chest Pain","Pain, Procedural","Pain, Postoperative","Analgesia","Regional Anesthesia Morbidity","Anesthesia, Local",[206,207,208,209,210,211,212,213,214],"Superficial Serratus Anterior Plane Block (SSAP)","Superficial Parasternal Intercostal Plane Block (SPIP)","Pectoserratus Plane Blocks (PSP)","Regional anaesthesia","Subcutaneous implantable defibrillator (S-ICD)","thorax blockade","less invasive","implantation","pain treatment","2024-07-23",{"date":217,"type":37},"2024-07-25",{"date":219,"type":37},"2024-06-16",{"date":221,"type":20},"2025-12-01",{"name":223,"class":44},"4th Military Clinical Hospital with Polyclinic, Poland",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":234,"studyType":88,"phases":4,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":247},"100503479","end---vt-cohort-study-100503479","NCT05835791","END - VT Cohort Study","Prospective Cohort for the sEcoNDary Prevention of Ventricular Tachycardia in Patients With Cardiomyopathies (END-VT) Study","END VT","Inclusion Criteria:\n\n1. Documented sustained ventricular arrhythmia (\\>30 seconds as documented by an ECG, cardiac monitor, AED, and\u002For intracardiac pacemaker\u002FICD electrograms (EGMs);\n2. First (new) diagnosis of VT;\n3. Presence of or plan for ICD implant during index hospitalization;\n4. Diagnosis of cardiomyopathy (ie. ICM, hypertrophic, dilated, restrictive, arrhythmogenic cardiomyopathy, or other scar),\n5. ICD clinic follow-up planned, and\n6. Age \\>18 years old\n\nExclusion Criteria:\n\n1\\) Patients with VT due to a reversible cause",{"count":233,"type":20},2454,"3 Years","Ventricular tachycardia (VT) is a life-threatening cardiac rhythm disturbance which leads to sudden cardiac death (SCD), ventricular fibrillation, electrical storm, hemodynamic collapse, and syncope. VT patients with cardiomyopathy (diseased\u002Fscarred cardiac muscle) have the highest risk of SCD (\\\u003C1-4%) and recurrent VTs (15-35%). Although an implantable cardiac defibrillator (ICD) is the most effective treatment option to prevent SCD, it does not eliminate it. Without VT prevention, recurrent VT and ICD shocks may increase the risk of heart failure and death.\n\nThe primary objective is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with ventricular tachycardia (VT) by the creation of a prospective, multicenter, longitudinal cohort. Also, the investigators will evaluate the epidemiology of VT, adherence to guidelines, safety, effectiveness, and cost-effectiveness of current treatment options for secondary prevention of VT in the real-world Canadian VT population.",[26,237,27],"Implantable Defibrillator User","2024-07-15",{"date":240,"type":37},"2024-07-16",{"date":242,"type":37},"2024-01-12",{"date":244,"type":20},"2029-04-30",{"name":246,"class":44},"Nova Scotia Health Authority",3,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":4,"enrollmentInfo":256,"targetDuration":258,"studyType":88,"phases":4,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":45},"100444798","monaldi-hospital-rhythm-registry-100444798","NCT05072119","Monaldi Hospital Rhythm Registry","Registry of Patients Underwent Cardiac Implanted Electronic Device Implantation at Monaldi Hospital","Inclusion Criteria:\n\n* All consecutive patients underwent PM\u002FICD\u002FILR implantation\n* Patient is willing and able to sign an authorization to use and disclose health information or an Informed Consent\n* Patient must be able to attend all required follow-up visits at the study center for at least 12 months\n\nExclusion Criteria:\n\n* No informed consent\n* Patient is participating in another clinical study that may have an impact on the study endpoint\n\nExclusion Criteria:\n\n* No informed consent","14 Years",{"count":257,"type":20},5000,"20 Years","The study is a prospective registry. Consecutive patients with indications of implant \u002F replacement or upgrade of pacemaker (PM), implantable cardioverter defibrillator (ICD), Implanted loop recorder (ILR) will be enrolled.\n\nThe primary objective of the study is to describe the clinical events during a long-term follow-up of non-selected population of patients implanted with an PM, ICD or ILR.",[92,27,261],"Implanted Loop Recorder","2021-10-08",{"date":264,"type":37},"2021-10-15",{"date":266,"type":37},"2015-01-07",{"date":268,"type":20},"2050-01",{"name":270,"class":44},"University of Campania Luigi Vanvitelli"]